#SFHS2609394AFrance adds Onivyde to the hospital add-on reimbursement list for metastatic pancreatic cancer
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order adds Onivyde, a pegylated liposomal irinotecan medicine marketed by Servier, to the list of hospital medicines that can be billed separately from standard hospitalization services in France. The extra reimbursement applies only when Onivyde is used with oxaliplatin, 5-fluorouracil and leucovorin as first-line treatment for adults with metastatic pancreatic adenocarcinoma. Hospitals and oncology teams can rely on this listing for eligible billing, but only for this specific indication.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds Onivyde 4.3 mg/ml infusion concentrate to the list of medicines reimbursed separately from hospitalization services
- Limits extra reimbursement to first-line treatment of adult patients with metastatic pancreatic adenocarcinoma
- Requires use in combination with oxaliplatin, 5-fluorouracil and leucovorin for the listed indication
Obligations
What this law requires
Hospitals may bill ONIVYDE PEGYLATED LIPOSOMAL 4.3 mg/ml separately from hospitalization services only when it is used with oxaliplatin, 5-fluorouracil and leucovorin as first-line treatment for adult patients with metastatic pancreatic adenocarcinoma.
For separate reimbursement, hospitals must identify the listed medicine using UCD code 3400894264910 for ONIVYDE 4.3MG/ML PERF FL10ML marketed by Servier.